LAUSR

BACKGROUND Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets. OBJECTIVE The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets. RESULTS AND CONCLUSION There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.